A Study on Anti-tumour Activity of Orally Administered RO4929097, a Gamma-secretase Inhibitor, as a Single Agent in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 10 Jun 2016
At a glance
- Drugs RG 4733 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Roche
- 20 Apr 2012 Planned number of patients changed from 20 to 32 as reported by European Clinical Trials Database.
- 07 Aug 2010 Status changed from recruiting to suspended due to pharmacokinetic liabilities and not related to safety, as reported by Roche record.
- 25 Mar 2010 Planned number of patients changed from 38 to 20 as reported by Roche.